BIAF · bioAffinity Technologies, Inc. · Executive Compensation
$1.76
-0.09 (-4.86%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at September 30, 2026, of $2.6 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Nov 6, 2026
Market Cap
$3.37M
Shares
1.82M
Volume · Nov 20
16.51K
Avg daily vol (63 sessions)
3.6M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $434,983 |
| J. Michael Edwards | Chief Financial Officer | $368,455 |
| Steven Girgenti | Executive Chairman | $261,860 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $477,155 |
| Steven Girgenti | Executive Chairman | $366,679 |
| J. Michael Edwards | Chief Financial Officer | $273,213 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $424,168 |
| Michael Dougherty | Vice President and CFO | $338,919 |
| Steven Girgenti | Executive Chairman | $248,745 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $351,287 |
| Vivienne Rebel | EVP; Chief Science & Medical Officer | $257,566 |
| Steven Girgenti | Executive Chairman | $153,333 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Maria Zannes | President and CEO | $264,404 |
| Vivienne Rebel | EVP; Chief Science & Medical Officer | $249,790 |
| Steven Girgenti | Executive Chairman | $193,222 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John J. Oppenheimer | member of the Board | Appointed | 2025-08-18 |
|
Gary Rubin
“Mr. Rubin’s resignation was not the result of any disagreement with the Company or the Board on any matters relating to the operations, policies or practices.”
|
Board | Resigned | 2025-08-18 |
| Roberto Rios | member of the Board | Appointed | 2025-08-18 |
| J. Michael Edwards | Chief Financial Officer | Appointed | 2024-10-10 |
| Michael Edwards | Interim Chief Financial Officer and Principal Accounting Officer | Appointed | 2024-08-23 |
|
Michael Dougherty
“Mr. Dougherty's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices, including any matters concerning the Company's controls or any financial or accounting-related matters or disclosures.”
|
Chief Financial Officer and Principal Accounting Officer | Resigned | 2024-08-23 |
| Jamie Platt | Director | Appointed | 2024-06-05 |
| Gary Rubin | Director | Appointed | 2024-06-05 |
| Roby Joyce | Director | Appointed | 2024-06-05 |
| Robert Anderson | Director |
Already on the board
Since at least 2014: re-election or new board role
|
2024-06-05 |
| Stuart Diamond | Director |
Already on the board
Since at least 2022: re-election or new board role
|
2024-06-05 |
| Peter Knight | Director |
Already on the board
Since at least 2018: re-election or new board role
|
2024-06-05 |
| Steven Girgenti | Director | Appointed | 2024-06-05 |
| Maria Zannes | Director |
Already on the board
Since at least 2014: re-election or new board role
|
2024-06-05 |
|
Mohsin Y. Meghji
“On December 1, 2023, Mohsin Y. Meghji resigned from the Board of Directors, effective immediately, for personal reasons, and not due to any disagreement with the Company or its operations, policies or practices.”
|
Board of Directors | Resigned | 2023-12-05 |
| Jamie Platt, Ph.D. | director | Appointed | 2023-12-05 |
| Roby Joyce, M.D. | Laboratory Director and Medical Director of Precision Pathology Laboratory Services, LLC | Appointed | 2023-09-20 |
| Xavier Reveles | Chief Operating Officer | Appointed | 2023-09-20 |
| Roby P. Joyce | Board of Directors | Appointed | 2023-09-20 |
| Gary Rubin | director | Appointed | 2023-06-07 |
| Peter Knight | director |
Already on the board
Since at least 2018: re-election or new board role
|
2023-06-07 |
| Stuart Diamond | director | Appointed | 2023-06-07 |
| Mohsin Meghji | director | Appointed | 2023-06-07 |
| Robert Anderson | director |
Already on the board
Since at least 2014: re-election or new board role
|
2023-06-07 |
| Steven Girgenti | director | Appointed | 2023-06-07 |
Leadership
- Maria Zannes CEO, Board Member
- Steven Girgenti Chairman, Board Member
- J. Michael Edwards CFO
- James Michael Edwards CFO
- Michael Dougherty CFO
- Xavier Reveles COO
- Timothy P. Zannes General Counsel
- Gary Rubin Board Member
- Jamie Platt Board Member
- Jamie Platt, Ph.D. Board Member
- Jamie Platt, PhD Board Member
- John J. Oppenheimer Board Member
- John J. Oppenheimer, MD Board Member
- Maria Zannes, JD Board Member
- Mohsin Meghji Board Member
- Peter Knight Board Member
- Robert Anderson Board Member
- Roberto Rios Board Member
- Roby Joyce Board Member
- Roby Joyce, MD Board Member
- Roby P. Joyce Board Member
- To approve Board Member
- To approve a proposal to Board Member
- To approve an amendment Board Member
- To approve an anti-dilution Board Member
- To seek authorization to Board Member
Key facts
CIK
1712762
CUSIP
09076W406
13F (30d)
21 filings
14 filers
Visit website
Investor relations